Shares of DexCom, Inc. (NASDAQ:DXCM) have earned an average rating of “Buy” from the twenty-three ratings firms that are currently covering the stock, MarketBeat reports. Seven equities research analysts have rated the stock with a hold recommendation, fourteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $143.53.
A number of equities analysts recently commented on the company. UBS Group raised their target price on DexCom from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, January 8th. Oppenheimer set a $150.00 target price on DexCom and gave the company a “buy” rating in a report on Thursday, December 6th. Goldman Sachs Group upgraded DexCom from a “sell” rating to a “neutral” rating and set a $125.00 price target on the stock in a research note on Friday, October 19th. Morgan Stanley boosted their target price on DexCom from $130.00 to $150.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 11th. Finally, Jefferies Financial Group upped their price objective on DexCom to $148.00 and gave the company a “buy” rating in a research report on Wednesday, November 7th.
NASDAQ:DXCM traded up $1.97 during mid-day trading on Friday, reaching $142.02. The company’s stock had a trading volume of 7,443 shares, compared to its average volume of 1,242,183. The firm has a market cap of $12.56 billion, a PE ratio of -243.81 and a beta of 0.63. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43. DexCom has a 1 year low of $52.92 and a 1 year high of $152.69.
DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.29. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. The business had revenue of $266.70 million for the quarter, compared to analyst estimates of $242.72 million. The business’s quarterly revenue was up 44.5% on a year-over-year basis. Sell-side analysts anticipate that DexCom will post -0.12 EPS for the current fiscal year.
In other DexCom news, EVP Steven Robert Pacelli sold 3,114 shares of the company’s stock in a transaction dated Wednesday, January 23rd. The stock was sold at an average price of $149.74, for a total transaction of $466,290.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steven R. Altman sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 2nd. The stock was sold at an average price of $117.04, for a total value of $292,600.00. Following the sale, the director now owns 3,449 shares of the company’s stock, valued at $403,670.96. The disclosure for this sale can be found here. Insiders sold 75,026 shares of company stock valued at $10,289,837 over the last quarter. Insiders own 1.80% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of DXCM. First Hawaiian Bank lifted its holdings in DexCom by 75.6% during the 4th quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock worth $47,000 after buying an additional 170 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in DexCom during the fourth quarter valued at about $33,000. Hanseatic Management Services Inc. raised its holdings in DexCom by 4.9% during the fourth quarter. Hanseatic Management Services Inc. now owns 10,034 shares of the medical device company’s stock valued at $1,202,000 after buying an additional 473 shares in the last quarter. Advisory Research Inc. increased its stake in shares of DexCom by 17.2% in the third quarter. Advisory Research Inc. now owns 4,084 shares of the medical device company’s stock worth $584,000 after purchasing an additional 598 shares during the period. Finally, Oppenheimer & Co. Inc. increased its stake in shares of DexCom by 23.8% in the third quarter. Oppenheimer & Co. Inc. now owns 3,282 shares of the medical device company’s stock worth $469,000 after purchasing an additional 630 shares during the period. 99.17% of the stock is owned by institutional investors.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Recommended Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.